Quantum Bioarma: Catalyst-Driven Opportunity in MS & Alcohol Metabolism
"They've completed phase one clinical trials for Lucid MS with positive safety data. They've completed their 90-day oral toxicity study and toxioinetic studies which are key requirements for their FDA investigational new drug application. They're actively working towards phase 2 efficacy trials in actual MS patients. Now, let's talk about the second piece of the puzzle, which is Unbuzzed. This is a dietary supplement developed by Quantum Bioarma that's designed to accelerate alcohol metabolism. Study participants who took Unbuzzed after drinking saw their blood alcohol concentration drop more than 40% faster than the placebo group within just 30 minutes. And importantly, no adverse side effects were reported."
— Speaker
The sponsored segment outlines Quantum Bioarma's two main catalysts: their non-immunomodulatory multiple sclerosis compound, Lucid MS, which is progressing through clinical trials with positive safety data, and Unbuzzed, a dietary supplement that significantly accelerates alcohol metabolism as demonstrated in clinical trials. The commentary suggests potential upside driven by clinical progress in an expanding market and underscores the importance of due diligence.
Target:N/A
Horizon:Long-term >1 year Company CommentaryBullish Medium ConvictionScore: 7.6
Company Opinion •ZipTrader • Dec 22, 2025